Top

Clinical Orthopaedics and Related Research®

Published in:

01-02-2013 | Symposium: Papers Presented at the Annual Meetings of The Hip Society

Two-stage Treatment of Hip Periprosthetic Joint Infection Is Associated With a High Rate of Infection Control but High Mortality

Authors: Keith R. Berend, MD, Adolph V. Lombardi Jr, MD, Michael J. Morris, MD, Adam G. Bergeson, MD, Joanne B. Adams, BFA, Michael A. Sneller, BS

Published in: Clinical Orthopaedics and Related Research® | Issue 2/2013

Abstract

Background

Periprosthetic infection after total hip arthroplasty (THA) is a devastating complication. Reported rates of infection control range from 80% to 95% but mortality rates associated with treatment of infected THA are also substantial and we suspect underreported.

Questions/Purposes

For patients selected for two-stage treatment of infected THA we therefore determined (1) mortality; (2) rate of reimplantation; and (3) rate of reinfection.

Methods

We identified 202 patients (205 hips) with infected primary or revision THA treated with a two-stage protocol between 1996 and 2009 in our prospectively collected practice registry. Patients underwent two-stage treatment for infection, including removal of all implants and foreign material with implantation of an antibiotic-laden cement spacer in the first stage followed by intravenous culture-specific antibiotics for a minimum of 6 weeks. Second-stage reimplantation was performed if erythrocyte sedimentation rate and C-reactive protein were trending toward normal and the wound was well healed. Thirteen patients (13 hips) were lost to followup before 24 months. The minimum followup in surviving patients was 24 months or failure (average, 53 months; range, 24–180 months).

Results

Fourteen patients (7%; 14 hips) died before reimplantation and two were not candidates because of medical comorbidities. The 90-day mortality rate after the first-stage débridement was 4% (eight patients). Of the 186 patients (189 hips) who underwent reimplantation, 157 (83%) achieved control of the infection. Including all patients who underwent the first stage, survival and infection control after two-stage reimplantation was 76%.

Conclusion

Two-stage treatment of deep infection in primary and revision THA is associated with substantial mortality and a substantial failure rate from both reinfection and inability to perform the second stage.

Level of Evidence

Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Buttaro MA, Pusso R, Piccaluga F. Vancomycin-supplemented impacted bone allografts in infected hip arthroplasty. J Bone Joint Surg Br. 2005;87:314–319.PubMedCrossRef

Cabrita HB, Croci AT, de Camargo OP, de Lima ALLM. Prospective study of the treatment of infected hip arthroplasties with or without the use of an antibiotic-loaded cement spacer. Clinics (Sao Paulo). 2007;62:99–108.PubMedCrossRef

Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E. Oral antibiotics are effective for highly resistant hip arthroplasty infections. Clin Orthop Relat Res. 2009;467:2335–2342.PubMedCrossRef

Evans RP. Successful treatment of total hip and knee infection with articulating antibiotic components. Clin Orthop Relat Res. 2004;427:37–46.PubMedCrossRef

Fehring TK, Calton TF, Griffin WL. Cementless fixation in 2-stage reimplantation for periprosthetic sepsis. J Arthroplasty. 1999;14:175–181.PubMedCrossRef

Fink B, Grossmann A, Fuerst M, Schafer P, Fromelt L. Two-stage cementless revision of infected hip endoprostheses. Clin Orthop Relat Res. 2009;467:1848–1858.PubMedCrossRef

Garvin KL, Hanssen AD. Infection after total hip arthroplasty: past, present, and future. J Bone Joint Surg Am. 1995;77:1576–1588.PubMed

Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737–755.PubMed

Hofmann AA, Goldberg TD, Tanner AM, Cook TM. Ten-year experience using an articulating antibiotic cement hip spacer for the treatment of chronically infected total hip. J Arthroplasty. 2005;20:874–879.PubMedCrossRef

10.

Incavo SJ, Russell RD, Mathis KB, Adams H. Initial results of managing severe bone loss in infected total joint arthroplasty using customized articulating spacers. J Arthroplasty. 2009;24:607–613.PubMedCrossRef

11.

Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA, Guadagnoli E, Harris WH, Poss R, Baron JA. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am. 2001;83:1622–1629.PubMedCrossRef

12.

Klouche S, Sariali E, Mamoudy P. Total hip arthroplasty revision due to infection: a cost analysis approach. Orthop Traumatol Surg Res. 2010;96:124–132.PubMedCrossRef

13.

Koo K-H, Yang J-W, Cho S-H, Song H-R, Park H-B, Ha Y-C, Chang J-D, Kim S-Y, Kim Y-H. Impregnation of vancomycin, gentamicin, and cefotaxime in a cement spacer for two-stage cementless reconstruction in infected total hip arthroplasty. J Arthroplasty. 2001;16:882–892.PubMedCrossRef

14.

Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23:984–991.PubMedCrossRef

15.

Lange J, Troelsen A, Thomsen RW, Soballe K. Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis. Clin Epidemiol. 2012;4:57–73.PubMed

16.

Lee PTH, Clayton RA, Safir OA, Backstein DJ, Gross AE. Structural allograft as an option for treating infected hip arthroplasty with massive bone loss. Clin Orthop Relat Res. 2011;469:1016–1023.PubMedCrossRef

17.

Leung F, Richards CJ, Garbuz DS, Masri BA, Duncan CP. Two-stage total hip arthroplasty: how often does it control methicillin-resistant infection? Clin Orthop Relat Res. 2011;469:1009–1015.PubMedCrossRef

18.

Lieberman JR, Callaway GH, Salvati EA, Pellicci PM, Brause BD. Treatment of the infected total hip arthroplasty with a two-stage reimplantation protocol. Clin Orthop Relat Res. 1994;301:205–212.PubMed

19.

Lim S-J, Park J-C, Moon Y-W, Park Y-S. Treatment of periprosthetic hip infection caused by resistant microorganisms using 2-stage reimplantation protocol. J Arthroplasty. 2009;24:1264–1269.PubMedCrossRef

20.

Magnan B, Regis D, Biscaglia R, Barolozzi P. Preformed acrylic bone cement spacer loaded with antibiotics. Acta Orthop Scand. 2001;72:591–594.PubMedCrossRef

21.

McDonald DJ, Fitzgerald RH, Ilstrup DM. Two-stage reconstruction of a total hip arthroplasty because of infection. J Bone Joint Surg Am. 1989;71:828–834.PubMed

22.

Nestor BJ, Hanssen AD, Ferrer-Gonzalez R, Fitzgerald RH. The use of porous prosthesis in delayed reconstruction of total hip replacements that have failed because of infection. J Bone Joint Surg Am. 1994;76:349–359.PubMed

23.

Nusem J, Morgan DAF. Structural allografts for bone stock reconstruction in two-stage revision for infected total hip arthroplasty. Acta Orthop. 2006;77:92–97.PubMedCrossRef

24.

Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008;466:1710–1715.PubMedCrossRef

25.

Romano CL, Romano D, Logoluso N, Meani E. Long-stem versus short-stem preformed antibiotic-loaded cement spacers for two stage revision of infected total hip arthroplasty. Hip Int. 2010;20:26–33.PubMed

26.

Sanchez-Sotelo J, Berry DJ, Hanssen AD, Cabanela ME. Midterm to long-term followup of staged reimplantation for infected hip arthroplasty. Clin Orthop Relat Res. 2009;467:219–224.PubMedCrossRef

27.

Scharfenberger A, Clark M, Lavoie G, O’Connor G, Masson E, Beaupre LA. Treatment of an infected total hip replacement with the PROSTALAC system. Part 1: infection resolution. Can J Surg. 2007;50:24–28.PubMed

28.

Stockley I, Mockford BJ, Hoad-Reddick A, Norman P. The use of two-stage exchange arthroplasty with depot antibiotics in the absence of long-term antibiotic therapy in infected total hip replacement. J Bone Joint Surg Br. 2008;90:145–148.PubMed

29.

Takigami I, Yoshiki I, Ishimaru D, Ogawa H, Mori N, Shimizu T, Terabayashi N, Shimizu K. Two-stage revision surgery for hip prosthesis infection using antibiotic-loaded porous hydroxyapatite blocks. Arch Orthop Trauma Surg. 2010;130:1221–1226.PubMedCrossRef

30.

Toulson C, Walcott-Sapp S, Hur J, Salvati EA, Bostrum M, Brause BD, Westrich GH. Treatment of infected total hip arthroplasty with a 2-stage reimplantation protocol. J Arthroplasty. 2009;24:1051–1060.PubMedCrossRef

31.

Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. J Bone Joint Surg Am. 1996;78:512–523.PubMed

32.

Wang J-W, Chen C-E. Reimplantation of infected hip arthroplasties using bone allografts. Clin Orthop Relat Res. 1997;335:202–210.PubMedCrossRef

33.

Whittaker JP, Warren RE, Jones RS, Gregson PA. Is prolonged systemic antibiotic treatment essential in two-stage revision hip replacement for chronic Gram-positive infection? J Bone Joint Surg Br. 2009;91:44–51.PubMed

34.

Wolf CF, Gu NY, Doctor JN, Manner PA, Leopold SS. Comparison of one and two-stage revision of total hip arthroplasty complicated by infection. J Bone Joint Surg Am. 2011;93:631–639.PubMedCrossRef

35.

Yamamoto K, Miyagawa N, Masaoka T, Katori Y, Shishido T, Imakiire A. Clinical effectiveness of antibiotic-impregnated cement spacers for the treatment of infected implants of the hip joint. J Orthop Sci. 2003;8:823–828.PubMedCrossRef

36.

Younger ASE, Duncan CP, Masri BA, McGraw RW. The outcome of two-stage arthroplasty using a custom-made interval spacer to treat the infected hip. J Arthroplasty. 1997;12:615–623.PubMedCrossRef

37.

Zhan C, Kaczmarek R, Loyo-Berrios N, Sangl J, Bright RA. Incidence and short-term outcomes of primary and revision hip replacement in the United States. J Bone Joint Surg Am. 2007;89:526–533.PubMedCrossRef

Title: Two-stage Treatment of Hip Periprosthetic Joint Infection Is Associated With a High Rate of Infection Control but High Mortality
Authors: Keith R. Berend, MD
Adolph V. Lombardi Jr, MD
Michael J. Morris, MD
Adam G. Bergeson, MD
Joanne B. Adams, BFA
Michael A. Sneller, BS
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Clinical Orthopaedics and Related Research® / Issue 2/2013
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-012-2595-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Two-stage Treatment of Hip Periprosthetic Joint Infection Is Associated With a High Rate of Infection Control but High Mortality

Abstract

Background

Questions/Purposes

Methods

Results

Conclusion

Level of Evidence

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Questions/Purposes

Methods

Results

Conclusion

Level of Evidence

Please log in to get access to this content

Other articles of this Issue 2/2013

Reply to Letter to the Editor: Critically Assessing the Haiti Earthquake Response and the Barriers to Quality Orthopaedic Care

Case Report: Curetting Osteoid Osteoma of the Spine Using Combined Video-assisted Thoracoscopic Surgery and Navigation

Erratum to: Parecoxib Added to Ropivacaine Prolongs Duration of Axillary Brachial Plexus Blockade and Relieves Postoperative Pain

Validation of the Korean Version of the Oxford Knee Score in Patients Undergoing Total Knee Arthroplasty

Papers Presented at the Annual Meetings of The Hip Society 2012: Editorial Comment

Erratum to: Emerging Ideas: Novel 3-D Quantification and Classification of Cam Lesions in Patients With Femoroacetabular Impingement